Main Content start here
Main Layout
Report Description

Report Description

Forecast Period

2027-2031

Market Size (2025)

USD 24.81 Billion

CAGR (2026-2031)

7.51%

Fastest Growing Segment

Biosimilar

Largest Market

North America

Market Size (2031)

USD 38.31 Billion

Market Overview

The Global Human Insulin Market will grow from USD 24.81 Billion in 2025 to USD 38.31 Billion by 2031 at a 7.51% CAGR. The Global Human Insulin Market encompasses the commercial landscape for biosynthetic peptide hormones structurally identical to endogenous insulin, primarily used to regulate blood glucose in patients with diabetes mellitus. Growth is fundamentally driven by the escalating global burden of diabetes, which is accelerated by aging demographics, urbanization, and rising obesity rates necessitating consistent therapeutic management. According to the International Diabetes Federation, in 2024, approximately 589 million adults were living with diabetes worldwide, indicating a massive patient pool that requires effective medical intervention.

A primary challenge impeding market expansion is the high cost of manufacturing and distribution which limits product affordability in developing economies. These economic barriers often prevent optimal patient adherence and restrict market penetration in regions with the fastest growing disease prevalence. Consequently, strict pricing pressures and inadequate reimbursement frameworks in these areas create a substantial bottleneck for widespread insulin adoption and subsequent revenue growth.

Key Market Drivers

Technological Advancements in Insulin Delivery Systems are revolutionizing patient management by shifting preference from traditional vials and syringes to automated, minimally invasive devices. Innovations such as tubeless pumps, smart insulin pens, and closed-loop systems integrated with continuous glucose monitors significantly enhance adherence and glycemic control. This shift is evident in the surging demand for advanced delivery platforms which offer precision dosing and reduced lifestyle burden. For instance, according to Insulet Corporation, November 2024, in the 'Third Quarter 2024 Financial Results', total revenue for its Omnipod insulin management system increased by approximately 26% year-over-year, driven by strong adoption across both type 1 and type 2 diabetes segments. These technologies effectively address the market's need for improved therapeutic outcomes, thereby fueling robust sector growth.

Concurrently, the Growing Adoption of Cost-Effective Biosimilars is reshaping the competitive landscape by dismantling economic barriers to access. As patents for blockbuster insulin analogs expire, the introduction of high-quality biosimilar alternatives offers substantial cost savings for healthcare systems and patients, particularly in emerging markets where affordability is critical. This trend is accelerating volume uptake and expanding the treated patient pool. According to Biocon Limited, October 2024, in the 'Consolidated Financial Results for Q2 FY25', the company’s biosimilars business reported a 19% year-over-year revenue growth on a like-for-like basis, underscoring the rising global demand for affordable insulin therapeutics. Furthermore, the financial magnitude of diabetes care emphasizes the urgency for such cost-efficient solutions; according to the International Diabetes Federation, in 2024, diabetes-related global health expenditure was estimated to surpass USD 1 trillion. These dynamics collectively propel market expansion while addressing sustainability in healthcare spending.

Download Free Sample Report

Key Market Challenges

The high cost of manufacturing and distribution presents a significant structural barrier to the expansion of the Global Human Insulin Market, particularly within developing economies. Producing biosynthetic peptide hormones requires complex, capital-intensive biotechnology facilities and rigorous quality control measures, which establishes a high baseline price for the final product. Furthermore, the logistical necessity of maintaining a strict cold chain during distribution adds substantial overhead, further inflating the cost to the end user. In regions with limited healthcare infrastructure and lower average incomes, these accumulated costs render the therapy economically inaccessible for a large segment of the population, effectively capping market penetration.

This economic disconnect severely impacts market potential because the highest demand growth is currently concentrated in these financially constrained regions. According to the International Diabetes Federation, in 2024, over 75 percent of adults with diabetes were living in low- and middle-income countries. This statistic underscores the magnitude of the challenge, as the vast majority of the potential patient pool resides in areas where the pricing structure is prohibitive. Consequently, the market faces a bottleneck where revenue growth is stifled by the inability of the primary growth demographic to afford the necessary treatment.

Key Market Trends

The emergence of once-weekly basal insulin formulations is fundamentally altering the treatment landscape by addressing the significant burden of daily injection regimens. Pharmaceutical developers are prioritizing ultra-long-acting analogs that maintain stable glycemic control over seven days, thereby aiming to overcome injection fatigue and improve long-term therapeutic adherence among patients with type 2 diabetes. This formulation innovation directly targets the lifestyle constraints associated with traditional daily basal therapies, moving beyond device improvements to chemical structural advancements. For instance, according to Eli Lilly and Company, September 2024, in the 'QWINT-2 phase 3 trial', the company's once-weekly insulin efsitora alfa demonstrated non-inferiority to daily insulin degludec by reducing A1C levels by 1.34% compared to 1.26% in insulin-naïve adults.

Concurrently, the development of oral and non-invasive insulin delivery systems continues to attract significant investment as companies strive to eliminate the reliance on subcutaneous administration entirely. This trend is characterized by persistent clinical investigation into encapsulated oral formulations designed to withstand gastric degradation, offering a needle-free alternative that could substantially expand early insulin acceptance. Despite historical clinical hurdles, the pursuit of this technology remains active due to its potential to revolutionize patient convenience and bypass the psychological barriers of injectable therapies. Illustrating this continued effort, according to Oramed Pharmaceuticals, February 2024, the company announced plans to reinitiate a Phase 3 trial for its oral insulin candidate, ORMD-0801, focusing on a specific subpopulation of patients that exhibited significant responsiveness in previous data analyses.

Segmental Insights

The Biosimilar segment is projected to emerge as the fastest-growing category in the Global Human Insulin Market. This rapid expansion is primarily driven by the expiration of patents for major branded biologics, which allows for the introduction of cost-competitive alternatives. Regulatory bodies such as the U.S. Food and Drug Administration and the European Medicines Agency have established clear guidelines to streamline approvals, further encouraging product development. Consequently, healthcare systems globally are increasingly adopting biosimilars to manage rising healthcare costs, ensuring broader patient access to essential diabetes treatments while maintaining clinical standards.

Regional Insights

North America holds the leading position in the global human insulin market due to the high incidence of diabetes and established healthcare systems. The dominance is supported by the presence of major pharmaceutical manufacturers and extensive health insurance coverage that facilitates patient access to treatment. Furthermore, the United States Food and Drug Administration (USFDA) plays a vital role in ensuring product safety and streamlining approvals for insulin therapies. These factors, combined with increasing awareness regarding diabetes management, drive the continued expansion of the regional market.

Recent Developments

  • In December 2024, Sanofi announced a significant investment of approximately €1 billion to establish a new insulin production base in the Beijing Economic-Technological Development Area. This strategic initiative, formalized through a memorandum of understanding with local authorities, aimed to enhance the company's manufacturing capabilities and supply chain resilience in China. The new facility was designed to produce a range of insulin products to meet the growing demand for diabetes management solutions in the region, reinforcing the company's long-term commitment to the Chinese market and its local patient population.
  • In December 2024, Eli Lilly and Company and EVA Pharma announced the regulatory approval and subsequent launch of the first locally manufactured insulin glargine in Egypt. This milestone was achieved under a collaboration agreement established to improve access to affordable insulin in low- and middle-income countries. The Egyptian Drug Authority granted approval for the product, which was manufactured at EVA Pharma’s facilities using active pharmaceutical ingredients supplied by Eli Lilly. The partnership focused on localizing the manufacturing process to ensure a sustainable supply of high-quality insulin for patients in Africa.
  • In September 2024, Gan & Lee Pharmaceuticals presented positive Phase 1 clinical trial results for GZR4, its investigational once-weekly insulin analog, at the 60th Annual Meeting of the European Association for the Study of Diabetes (EASD). The data from the Phase 1a and Phase 1b studies demonstrated that the candidate possessed a safety and tolerability profile comparable to daily basal insulin while maintaining stable glucose-lowering effects over a one-week period. The company highlighted that these findings supported the potential of GZR4 to reduce the injection burden for patients with type 2 diabetes, positioning it as a potential competitor in the emerging weekly insulin market segment.
  • In July 2024, Novo Nordisk received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its Biologics License Application for insulin icodec, a once-weekly basal insulin intended for the treatment of diabetes mellitus. The regulatory agency declined to approve the application at that time, citing requests related to the manufacturing process and the proposed indication for type 1 diabetes. This decision followed a meeting of the Endocrinologic and Metabolic Drugs Advisory Committee, which had previously determined that the available data was insufficient to conclude that the benefits of the product outweighed the risks for patients with type 1 diabetes.

Key Market Players

  • Novo Nordisk A/S
  • Eli Lilly and Company
  • Sanofi S.A.
  • Biocon Limited
  • Wockhardt Limited
  • Julphar
  • Tonghua Dongbao Pharmaceutical Co., Ltd.
  • B. Braun Melsungen AG
  • Pfizer Inc.
  • Ypsomed AG

By Indication

By Brand

By Route of Administration

By Type

By Onset Time

By Products

By Region

  • Type I Diabetes
  • Type II Diabetes
  • Lantus
  • Humulin R
  • Novolin R
  • Humulin N
  • Exubera
  • Afrezza
  • Novolin N
  • Subcutaneous
  • Transdermal
  • Nasal
  • Intravenous
  • Oral and Others
  • Basal
  • Bolus
  • Pre-mixed
  • Biosimilar
  • Traditional
  • Rapid acting
  • Short-acting
  • Intermediate acting
  • Long acting
  • Pre-Mixed
  • Inhaled
  • Ultra-long Acting
  • Insulin Pens
  • Insulin Pumps
  • Infusion System
  • Injections
  • North America
  • Europe
  • Asia Pacific
  • South America
  • Middle East & Africa

Report Scope:

In this report, the Global Human Insulin Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

  • Human Insulin Market, By Indication:
  • Type I Diabetes
  • Type II Diabetes
  • Human Insulin Market, By Brand:
  • Lantus
  • Humulin R
  • Novolin R
  • Humulin N
  • Exubera
  • Afrezza
  • Novolin N
  • Human Insulin Market, By Route of Administration:
  • Subcutaneous
  • Transdermal
  • Nasal
  • Intravenous
  • Oral and Others
  • Human Insulin Market, By Type:
  • Basal
  • Bolus
  • Pre-mixed
  • Biosimilar
  • Traditional
  • Human Insulin Market, By Onset Time:
  • Rapid acting
  • Short-acting
  • Intermediate acting
  • Long acting
  • Pre-Mixed
  • Inhaled
  • Ultra-long Acting
  • Human Insulin Market, By Products:
  • Insulin Pens
  • Insulin Pumps
  • Infusion System
  • Injections
  • Human Insulin Market, By Region:
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Human Insulin Market.

Available Customizations:

Global Human Insulin Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Global Human Insulin Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]

Table of content

Table of content

1.    Product Overview

1.1.  Market Definition

1.2.  Scope of the Market

1.2.1.  Markets Covered

1.2.2.  Years Considered for Study

1.2.3.  Key Market Segmentations

2.    Research Methodology

2.1.  Objective of the Study

2.2.  Baseline Methodology

2.3.  Key Industry Partners

2.4.  Major Association and Secondary Sources

2.5.  Forecasting Methodology

2.6.  Data Triangulation & Validation

2.7.  Assumptions and Limitations

3.    Executive Summary

3.1.  Overview of the Market

3.2.  Overview of Key Market Segmentations

3.3.  Overview of Key Market Players

3.4.  Overview of Key Regions/Countries

3.5.  Overview of Market Drivers, Challenges, Trends

4.    Voice of Customer

5.    Global Human Insulin Market Outlook

5.1.  Market Size & Forecast

5.1.1.  By Value

5.2.  Market Share & Forecast

5.2.1.  By Indication (Type I Diabetes, Type II Diabetes)

5.2.2.  By Brand (Lantus, Humulin R, Novolin R, Humulin N, Exubera, Afrezza, Novolin N)

5.2.3.  By Route of Administration (Subcutaneous, Transdermal, Nasal, Intravenous, Oral and Others)

5.2.4.  By Type (Basal, Bolus, Pre-mixed, Biosimilar, Traditional)

5.2.5.  By Onset Time (Rapid acting, Short-acting, Intermediate acting, Long acting, Pre-Mixed, Inhaled, Ultra-long Acting)

5.2.6.  By Products (Insulin Pens, Insulin Pumps, Infusion System, Injections)

5.2.7.  By Region

5.2.8.  By Company (2025)

5.3.  Market Map

6.    North America Human Insulin Market Outlook

6.1.  Market Size & Forecast

6.1.1.  By Value

6.2.  Market Share & Forecast

6.2.1.  By Indication

6.2.2.  By Brand

6.2.3.  By Route of Administration

6.2.4.  By Type

6.2.5.  By Onset Time

6.2.6.  By Products

6.2.7.  By Country

6.3.    North America: Country Analysis

6.3.1.    United States Human Insulin Market Outlook

6.3.1.1.  Market Size & Forecast

6.3.1.1.1.  By Value

6.3.1.2.  Market Share & Forecast

6.3.1.2.1.  By Indication

6.3.1.2.2.  By Brand

6.3.1.2.3.  By Route of Administration

6.3.1.2.4.  By Type

6.3.1.2.5.  By Onset Time

6.3.1.2.6.  By Products

6.3.2.    Canada Human Insulin Market Outlook

6.3.2.1.  Market Size & Forecast

6.3.2.1.1.  By Value

6.3.2.2.  Market Share & Forecast

6.3.2.2.1.  By Indication

6.3.2.2.2.  By Brand

6.3.2.2.3.  By Route of Administration

6.3.2.2.4.  By Type

6.3.2.2.5.  By Onset Time

6.3.2.2.6.  By Products

6.3.3.    Mexico Human Insulin Market Outlook

6.3.3.1.  Market Size & Forecast

6.3.3.1.1.  By Value

6.3.3.2.  Market Share & Forecast

6.3.3.2.1.  By Indication

6.3.3.2.2.  By Brand

6.3.3.2.3.  By Route of Administration

6.3.3.2.4.  By Type

6.3.3.2.5.  By Onset Time

6.3.3.2.6.  By Products

7.    Europe Human Insulin Market Outlook

7.1.  Market Size & Forecast

7.1.1.  By Value

7.2.  Market Share & Forecast

7.2.1.  By Indication

7.2.2.  By Brand

7.2.3.  By Route of Administration

7.2.4.  By Type

7.2.5.  By Onset Time

7.2.6.  By Products

7.2.7.  By Country

7.3.    Europe: Country Analysis

7.3.1.    Germany Human Insulin Market Outlook

7.3.1.1.  Market Size & Forecast

7.3.1.1.1.  By Value

7.3.1.2.  Market Share & Forecast

7.3.1.2.1.  By Indication

7.3.1.2.2.  By Brand

7.3.1.2.3.  By Route of Administration

7.3.1.2.4.  By Type

7.3.1.2.5.  By Onset Time

7.3.1.2.6.  By Products

7.3.2.    France Human Insulin Market Outlook

7.3.2.1.  Market Size & Forecast

7.3.2.1.1.  By Value

7.3.2.2.  Market Share & Forecast

7.3.2.2.1.  By Indication

7.3.2.2.2.  By Brand

7.3.2.2.3.  By Route of Administration

7.3.2.2.4.  By Type

7.3.2.2.5.  By Onset Time

7.3.2.2.6.  By Products

7.3.3.    United Kingdom Human Insulin Market Outlook

7.3.3.1.  Market Size & Forecast

7.3.3.1.1.  By Value

7.3.3.2.  Market Share & Forecast

7.3.3.2.1.  By Indication

7.3.3.2.2.  By Brand

7.3.3.2.3.  By Route of Administration

7.3.3.2.4.  By Type

7.3.3.2.5.  By Onset Time

7.3.3.2.6.  By Products

7.3.4.    Italy Human Insulin Market Outlook

7.3.4.1.  Market Size & Forecast

7.3.4.1.1.  By Value

7.3.4.2.  Market Share & Forecast

7.3.4.2.1.  By Indication

7.3.4.2.2.  By Brand

7.3.4.2.3.  By Route of Administration

7.3.4.2.4.  By Type

7.3.4.2.5.  By Onset Time

7.3.4.2.6.  By Products

7.3.5.    Spain Human Insulin Market Outlook

7.3.5.1.  Market Size & Forecast

7.3.5.1.1.  By Value

7.3.5.2.  Market Share & Forecast

7.3.5.2.1.  By Indication

7.3.5.2.2.  By Brand

7.3.5.2.3.  By Route of Administration

7.3.5.2.4.  By Type

7.3.5.2.5.  By Onset Time

7.3.5.2.6.  By Products

8.    Asia Pacific Human Insulin Market Outlook

8.1.  Market Size & Forecast

8.1.1.  By Value

8.2.  Market Share & Forecast

8.2.1.  By Indication

8.2.2.  By Brand

8.2.3.  By Route of Administration

8.2.4.  By Type

8.2.5.  By Onset Time

8.2.6.  By Products

8.2.7.  By Country

8.3.    Asia Pacific: Country Analysis

8.3.1.    China Human Insulin Market Outlook

8.3.1.1.  Market Size & Forecast

8.3.1.1.1.  By Value

8.3.1.2.  Market Share & Forecast

8.3.1.2.1.  By Indication

8.3.1.2.2.  By Brand

8.3.1.2.3.  By Route of Administration

8.3.1.2.4.  By Type

8.3.1.2.5.  By Onset Time

8.3.1.2.6.  By Products

8.3.2.    India Human Insulin Market Outlook

8.3.2.1.  Market Size & Forecast

8.3.2.1.1.  By Value

8.3.2.2.  Market Share & Forecast

8.3.2.2.1.  By Indication

8.3.2.2.2.  By Brand

8.3.2.2.3.  By Route of Administration

8.3.2.2.4.  By Type

8.3.2.2.5.  By Onset Time

8.3.2.2.6.  By Products

8.3.3.    Japan Human Insulin Market Outlook

8.3.3.1.  Market Size & Forecast

8.3.3.1.1.  By Value

8.3.3.2.  Market Share & Forecast

8.3.3.2.1.  By Indication

8.3.3.2.2.  By Brand

8.3.3.2.3.  By Route of Administration

8.3.3.2.4.  By Type

8.3.3.2.5.  By Onset Time

8.3.3.2.6.  By Products

8.3.4.    South Korea Human Insulin Market Outlook

8.3.4.1.  Market Size & Forecast

8.3.4.1.1.  By Value

8.3.4.2.  Market Share & Forecast

8.3.4.2.1.  By Indication

8.3.4.2.2.  By Brand

8.3.4.2.3.  By Route of Administration

8.3.4.2.4.  By Type

8.3.4.2.5.  By Onset Time

8.3.4.2.6.  By Products

8.3.5.    Australia Human Insulin Market Outlook

8.3.5.1.  Market Size & Forecast

8.3.5.1.1.  By Value

8.3.5.2.  Market Share & Forecast

8.3.5.2.1.  By Indication

8.3.5.2.2.  By Brand

8.3.5.2.3.  By Route of Administration

8.3.5.2.4.  By Type

8.3.5.2.5.  By Onset Time

8.3.5.2.6.  By Products

9.    Middle East & Africa Human Insulin Market Outlook

9.1.  Market Size & Forecast

9.1.1.  By Value

9.2.  Market Share & Forecast

9.2.1.  By Indication

9.2.2.  By Brand

9.2.3.  By Route of Administration

9.2.4.  By Type

9.2.5.  By Onset Time

9.2.6.  By Products

9.2.7.  By Country

9.3.    Middle East & Africa: Country Analysis

9.3.1.    Saudi Arabia Human Insulin Market Outlook

9.3.1.1.  Market Size & Forecast

9.3.1.1.1.  By Value

9.3.1.2.  Market Share & Forecast

9.3.1.2.1.  By Indication

9.3.1.2.2.  By Brand

9.3.1.2.3.  By Route of Administration

9.3.1.2.4.  By Type

9.3.1.2.5.  By Onset Time

9.3.1.2.6.  By Products

9.3.2.    UAE Human Insulin Market Outlook

9.3.2.1.  Market Size & Forecast

9.3.2.1.1.  By Value

9.3.2.2.  Market Share & Forecast

9.3.2.2.1.  By Indication

9.3.2.2.2.  By Brand

9.3.2.2.3.  By Route of Administration

9.3.2.2.4.  By Type

9.3.2.2.5.  By Onset Time

9.3.2.2.6.  By Products

9.3.3.    South Africa Human Insulin Market Outlook

9.3.3.1.  Market Size & Forecast

9.3.3.1.1.  By Value

9.3.3.2.  Market Share & Forecast

9.3.3.2.1.  By Indication

9.3.3.2.2.  By Brand

9.3.3.2.3.  By Route of Administration

9.3.3.2.4.  By Type

9.3.3.2.5.  By Onset Time

9.3.3.2.6.  By Products

10.    South America Human Insulin Market Outlook

10.1.  Market Size & Forecast

10.1.1.  By Value

10.2.  Market Share & Forecast

10.2.1.  By Indication

10.2.2.  By Brand

10.2.3.  By Route of Administration

10.2.4.  By Type

10.2.5.  By Onset Time

10.2.6.  By Products

10.2.7.  By Country

10.3.    South America: Country Analysis

10.3.1.    Brazil Human Insulin Market Outlook

10.3.1.1.  Market Size & Forecast

10.3.1.1.1.  By Value

10.3.1.2.  Market Share & Forecast

10.3.1.2.1.  By Indication

10.3.1.2.2.  By Brand

10.3.1.2.3.  By Route of Administration

10.3.1.2.4.  By Type

10.3.1.2.5.  By Onset Time

10.3.1.2.6.  By Products

10.3.2.    Colombia Human Insulin Market Outlook

10.3.2.1.  Market Size & Forecast

10.3.2.1.1.  By Value

10.3.2.2.  Market Share & Forecast

10.3.2.2.1.  By Indication

10.3.2.2.2.  By Brand

10.3.2.2.3.  By Route of Administration

10.3.2.2.4.  By Type

10.3.2.2.5.  By Onset Time

10.3.2.2.6.  By Products

10.3.3.    Argentina Human Insulin Market Outlook

10.3.3.1.  Market Size & Forecast

10.3.3.1.1.  By Value

10.3.3.2.  Market Share & Forecast

10.3.3.2.1.  By Indication

10.3.3.2.2.  By Brand

10.3.3.2.3.  By Route of Administration

10.3.3.2.4.  By Type

10.3.3.2.5.  By Onset Time

10.3.3.2.6.  By Products

11.    Market Dynamics

11.1.  Drivers

11.2.  Challenges

12.    Market Trends & Developments

12.1.  Merger & Acquisition (If Any)

12.2.  Product Launches (If Any)

12.3.  Recent Developments

13.    Global Human Insulin Market: SWOT Analysis

14.    Porter's Five Forces Analysis

14.1.  Competition in the Industry

14.2.  Potential of New Entrants

14.3.  Power of Suppliers

14.4.  Power of Customers

14.5.  Threat of Substitute Products

15.    Competitive Landscape

15.1.  Novo Nordisk A/S

15.1.1.  Business Overview

15.1.2.  Products & Services

15.1.3.  Recent Developments

15.1.4.  Key Personnel

15.1.5.  SWOT Analysis

15.2.  Eli Lilly and Company

15.3.  Sanofi S.A.

15.4.  Biocon Limited

15.5.  Wockhardt Limited

15.6.  Julphar

15.7.  Tonghua Dongbao Pharmaceutical Co., Ltd.

15.8.  B. Braun Melsungen AG

15.9.  Pfizer Inc.

15.10.  Ypsomed AG

16.    Strategic Recommendations

17.    About Us & Disclaimer

Figures and Tables

Figure 1: Global Human Insulin Market Size, By Volume (Million Units), By Value (USD Billion), 2015-2025F

Figure 2: Global Human Insulin Market Share, By Indication, By Value, 2015-2025F

Figure 3: Global Human Insulin Market Share, By Brand, By Value, 2015-2025F

Figure 4: Global Human Insulin Market Share, By Route of Administration, By Value, 2015-2025F

Figure 5: Global Human Insulin Market Share, By Type, By Value, 2015-2025F

Figure 6: Global Human Insulin Market Share, By Onset Time, By Value, 2015-2025F

Figure 7: Global Human Insulin Market Share, By Products, By Value, 2015-2025F

Figure 8: Global Human Insulin Market Share, By Company, By Value, 2019

Figure 9: Global Human Insulin Market Share, By Region, By Value, 2015-2025F

Figure 10: Global Human Insulin Market Share, By Region, By Value, 2015-2025F

Figure 11: Global Human Insulin Market Map, By Brand, Market Size (USD Billion) & Growth Rate (%)

Figure 12: Global Human Insulin Market Map, By Onset Time, Market Size (USD Billion) & Growth Rate (%)

Figure 13: Global Human Insulin Market Map, By Products, Market Size (USD Billion) & Growth Rate (%)

Figure 14: Global Human Insulin Market Map, By Region, Market Size (USD Billion) & Growth Rate (%)

Figure 15: North America Human Insulin Market Size, By Volume (Million Units), By Value (USD Billion), 2015-2025F

Figure 16: North America Human Insulin Market Share, By Indication, By Value, 2015-2025F

Figure 17: North America Human Insulin Market Share, By Brand, By Value, 2015-2025F

Figure 18: North America Human Insulin Market Share, By Route of Administration, By Value, 2015-2025F

Figure 19: North America Human Insulin Market Share, By Type, By Value, 2015-2025F

Figure 20: North America Human Insulin Market Share, By Onset Time, By Value, 2015-2025F

Figure 21: North America Human Insulin Market Share, By Products, By Value, 2015-2025F

Figure 22: North America Human Insulin Market Share, By Country, By Value, 2015-2025F

Figure 23: North America Human Insulin Market Map, By Brand, Market Size (USD Billion) & Growth Rate (%)

Figure 24: United States Human Insulin Market Size, By Volume (Million Units), By Value (USD Billion), 2015-2025F

Figure 25: Total Number of Diabetes patients in United States, By Value (Millions), 2019, 2030, 2045

Figure 26: United States Human Insulin Market Share, By Indication, By Value, 2015-2025F

Figure 27: United States Human Insulin Market Share, By Brand, By Value, 2015-2025F

Figure 28: United States Human Insulin Market Share, By Route of Administration, By Value, 2015-2025F

Figure 29:  United States Human Insulin Market Share, By Type, By Value, 2015-2025F

Figure 30: United States Human Insulin Market Share, By Onset Time, By Value, 2015-2025F

Figure 31: United States Human Insulin Market Share, By Products, By Value, 2015-2025F

Figure 32: Canada Human Insulin Market Size, By Volume (Million Units), By Value (USD Billion), 2015-2025F

Figure 33: Total Number of Diabetes patients in Canada, By Value (1000’s), 2010, 2019, 2030, 2045

Figure 34: Canada Human Insulin Market Share, By Indication, By Value, 2015-2025F

Figure 35: Canada Human Insulin Market Share, By Brand, By Value, 2015-2025F

Figure 36: Canada Human Insulin Market Share, By Route of Administration, By Value, 2015-2025F

Figure 37: Canada Human Insulin Market Share, By Type, By Value, 2015-2025F

Figure 38: Canada Human Insulin Market Share, By Onset Time, By Value, 2015-2025F

Figure 39: Canada Human Insulin Market Share, By Products, By Value, 2015-2025F

Figure 40: Mexico Human Insulin Market Size, By Volume (Million Units), By Value (USD Billion), 2015-2025F

Figure 41: Total Number of Diabetes patients in Mexico, By Value (Millions), 2019, 2030, 2045

Figure 42: Mexico Human Insulin Market Share, By Indication, By Value, 2015-2025F

Figure 43: Mexico Human Insulin Market Share, By Brand, By Value, 2015-2025F

Figure 44: Mexico Human Insulin Market Share, By Route of Administration, By Value, 2015-2025F

Figure 45: Mexico Human Insulin Market Share, By Type, By Value, 2015-2025F

Figure 46: Mexico Human Insulin Market Share, By Onset Time, By Value, 2015-2025F

Figure 47: Mexico Human Insulin Market Share, By Products, By Value, 2015-2025F

Figure 48: Europe Human Insulin Market Size, By Volume (Million Units), By Value (USD Billion), 2015-2025F

Figure 49: Europe Human Insulin Market Share, By Indication, By Value, 2015-2025F

Figure 50: Europe Human Insulin Market Share, By Brand, By Value, 2015-2025F

Figure 51: Europe Human Insulin Market Share, By Route of Administration, By Value, 2015-2025F

Figure 52: Europe Human Insulin Market Share, By Type, By Value, 2015-2025F

Figure 53: Europe Human Insulin Market Share, By Onset Time, By Value, 2015-2025F

Figure 54: Europe Human Insulin Market Share, By Products, By Value, 2015-2025F

Figure 55: Europe Human Insulin Market Share, By Country, By Value, 2015-2025F

Figure 56: Europe Human Insulin Market Map, By Brand, Market Size (USD Billion) & Growth Rate (%)

Figure 57: Germany Human Insulin Market Size, By Volume (Million Units), By Value (USD Billion), 2015-2025F

Figure 58: Germany undiagnosed and diagnosed diabetes cases, 2019

Figure 59: Germany Human Insulin Market Share, By Indication, By Value, 2015-2025F

Figure 60: Germany Human Insulin Market Share, By Brand, By Value, 2015-2025F

Figure 61: Germany Human Insulin Market Share, By Route of Administration, By Value, 2015-2025F

Figure 62: Germany Human Insulin Market Share, By Type, By Value, 2015-2025F

Figure 63: Germany Human Insulin Market Share, By Onset Time, By Value, 2015-2025F

Figure 64: Germany Human Insulin Market Share, By Products, By Value, 2015-2025F

Figure 65: United Kingdom Human Insulin Market Size, By Volume (Million Units), By Value (USD Billion), 2015-2025F

Figure 66: Different types of diabetes in United Kingdom, 2019

Figure 67: United Kingdom Human Insulin Market Share, By Indication, By Value, 2015-2025F

Figure 68: United Kingdom Human Insulin Market Share, By Brand, By Value, 2015-2025F

Figure 69: United Kingdom Human Insulin Market Share, By Route of Administration, By Value, 2015-2025F

Figure 70: United Kingdom Human Insulin Market Share, By Type, By Value, 2015-2025F

Figure 71: United Kingdom Human Insulin Market Share, By Onset Time, By Value, 2015-2025F

Figure 72: United Kingdom Human Insulin Market Share, By Products, By Value, 2015-2025F

Figure 73: France Human Insulin Market Size, By Volume (Million Units), By Value (USD Billion), 2015-2025F

Figure 74: France Healthcare Spending, By Value (USD Per Capita), 2015-2019

Figure 75: France Human Insulin Market Share, By Indication, By Value, 2015-2025F

Figure 76: France Human Insulin Market Share, By Brand, By Value, 2015-2025F

Figure 77: France Human Insulin Market Share, By Route of Administration, By Value, 2015-2025F

Figure 78: France Human Insulin Market Share, By Type, By Value, 2015-2025F

Figure 79: France Human Insulin Market Share, By Onset Time, By Value, 2015-2025F

Figure 80: France Human Insulin Market Share, By Products, By Value, 2015-2025F

Figure 81: Italy Human Insulin Market Size, By Volume (Million Units), By Value (USD Billion), 2015-2025F

Figure 82: Total Number of Diabetes patients in Italy, By Value (1000’s), 2010, 2019, 2030, 2045

Figure 83: Italy Human Insulin Market Share, By Indication, By Value, 2015-2025F

Figure 84: Italy Human Insulin Market Share, By Brand, By Value, 2015-2025F

Figure 85: Italy Human Insulin Market Share, By Route of Administration, By Value, 2015-2025F

Figure 86: Italy Human Insulin Market Share, By Type, By Value, 2015-2025F

Figure 87: Italy Human Insulin Market Share, By Onset Time, By Value, 2015-2025F

Figure 88: Italy Human Insulin Market Share, By Products, By Value, 2015-2025F

Figure 89: Spain Human Insulin Market Size, By Volume (Million Units), By Value (USD Billion), 2015-2025F

Figure 90: Total Number of Diabetes patients in Spain, By Value (1000’s), 2010, 2019, 2030, 2045

Figure 91: Spain Human Insulin Market Share, By Indication, By Value, 2015-2025F

Figure 92: Spain Human Insulin Market Share, By Brand, By Value, 2015-2025F

Figure 93: Spain Human Insulin Market Share, By Route of Administration, By Value, 2015-2025F

Figure 94: Spain Human Insulin Market Share, By Type, By Value, 2015-2025F

Figure 95: Spain Human Insulin Market Share, By Onset Time, By Value, 2015-2025F

Figure 96: Spain Human Insulin Market Share, By Products, By Value, 2015-2025F

Figure 97: Russia Human Insulin Market Size, By Volume (Million Units), By Value (USD Billion), 2015-2025F

Figure 98: Total Number of Diabetes patients in Russia, By Value (1000’s), 2010, 2019, 2030, 2045

Figure 99: Russia Human Insulin Market Share, By Indication, By Value, 2015-2025F

Figure 100: Russia Human Insulin Market Share, By Brand, By Value, 2015-2025F

Figure 101: Russia Human Insulin Market Share, By Route of Administration, By Value, 2015-2025F

Figure 102: Russia Human Insulin Market Share, By Type, By Value, 2015-2025F

Figure 103: Russia Human Insulin Market Share, By Onset Time, By Value, 2015-2025F

Figure 104: Russia Human Insulin Market Share, By Products, By Value, 2015-2025F

Figure 105: Asia-Pacific Human Insulin Market Size, By Volume (Million Units), By Value (USD Billion), 2015-2025F

Figure 106: Asia-Pacific Human Insulin Market Share, By Indication, By Value, 2015-2025F

Figure 107: Asia-Pacific Human Insulin Market Share, By Brand, By Value, 2015-2025F

Figure 108: Asia-Pacific Human Insulin Market Share, By Route of Administration, By Value, 2015-2025F

Figure 109: Asia-Pacific Human Insulin Market Share, By Type, By Value, 2015-2025F

Figure 110: Asia-Pacific Human Insulin Market Share, By Onset Time, By Value, 2015-2025F

Figure 111: Asia-Pacific Human Insulin Market Share, By Products, By Value, 2015-2025F

Figure 112: Asia-Pacific Human Insulin Market Share, By Country, By Value, 2015-2025F

Figure 113: Asia-Pacific Human Insulin Market Map, By Brand, Market Size (USD Billion) & Growth Rate (%)

Figure 114: China Human Insulin Market Size, By Volume (Million Units), By Value (USD Billion), 2015-2025F

Figure 115: Total Number of Diabetes patients in China, By Value (Millions), 2019, 2030, 2045

Figure 116: China Human Insulin Market Share, By Indication, By Value, 2015-2025F

Figure 117: China Human Insulin Market Share, By Brand, By Value, 2015-2025F

Figure 118: China Human Insulin Market Share, By Route of Administration, By Value, 2015-2025F

Figure 119: China Human Insulin Market Share, By Type, By Value, 2015-2025F

Figure 120: China Human Insulin Market Share, By Onset Time, By Value, 2015-2025F

Figure 121: China Human Insulin Market Share, By Products, By Value, 2015-2025F

Figure 122: India Human Insulin Market Size, By Volume (Million Units), By Value (USD Billion), 2015-2025F

Figure 123: Total Number of Diabetes patients in India, By Value (Millions), 2019, 2030, 2045

Figure 124: India Human Insulin Market Share, By Indication, By Value, 2015-2025F

Figure 125: India Human Insulin Market Share, By Brand, By Value, 2015-2025F

Figure 126: India Human Insulin Market Share, By Route of Administration, By Value, 2015-2025F

Figure 127: India Human Insulin Market Share, By Type, By Value, 2015-2025F

Figure 128: India Human Insulin Market Share, By Onset Time, By Value, 2015-2025F

Figure 129: India Human Insulin Market Share, By Products, By Value, 2015-2025F

Figure 130: Japan Human Insulin Market Size, By Volume (Million Units), By Value (USD Billion), 2015-2025F

Figure 131: Japan Total Health Expenditure as a share of GDP, 2015 - 2019

Figure 132: Japan Human Insulin Market Share, By Indication, By Value, 2015-2025F

Figure 133: Japan Human Insulin Market Share, By Brand, By Value, 2015-2025F

Figure 134: Japan Human Insulin Market Share, By Route of Administration, By Value, 2015-2025F

Figure 135: Japan Human Insulin Market Share, By Type, By Value, 2015-2025F

Figure 136: Japan Human Insulin Market Share, By Onset Time, By Value, 2015-2025F

Figure 137: Japan Human Insulin Market Share, By Products, By Value, 2015-2025F

Figure 138: South Korea Human Insulin Market Size, By Volume (Million Units), By Value (USD Billion), 2015-2025F

Figure 139: Total Number of Diabetes patients in South Korea, By Value (1000’s), 2010, 2019, 2030, 2045

Figure 140: South Korea Human Insulin Market Share, By Indication, By Value, 2015-2025F

Figure 141: South Korea Human Insulin Market Share, By Brand, By Value, 2015-2025F

Figure 142: South Korea Human Insulin Market Share, By Route of Administration, By Value, 2015-2025F

Figure 143: South Korea Human Insulin Market Share, By Type, By Value, 2015-2025F

Figure 144: South Korea Human Insulin Market Share, By Onset Time, By Value, 2015-2025F

Figure 145: South Korea Human Insulin Market Share, By Products, By Value, 2015-2025F

Figure 146: Australia Human Insulin Market Size, By Volume (Million Units), By Value (USD Billion), 2015-2025F

Figure 147: Total Number of Diabetes patients in Australia, By Value (1000’s), 2010, 2019, 2030, 2045

Figure 148: Australia Human Insulin Market Share, By Indication, By Value, 2015-2025F

Figure 149: Australia Human Insulin Market Share, By Brand, By Value, 2015-2025F

Figure 150: Australia Human Insulin Market Share, By Route of Administration, By Value, 2015-2025F

Figure 151: Australia Human Insulin Market Share, By Type, By Value, 2015-2025F

Figure 152: Australia Human Insulin Market Share, By Onset Time, By Value, 2015-2025F

Figure 153: Australia Human Insulin Market Share, By Products, By Value, 2015-2025F

Figure 154: Singapore Human Insulin Market Size, By Volume (Million Units), By Value (USD Billion), 2015-2025F

Figure 155: Total Number of Diabetes patients in Singapore, By Value (1000’s), 2010, 2019, 2030, 2045

Figure 156: Singapore Human Insulin Market Share, By Indication, By Value, 2015-2025F

Figure 157: Singapore Human Insulin Market Share, By Brand, By Value, 2015-2025F

Figure 158: Singapore Human Insulin Market Share, By Route of Administration, By Value, 2015-2025F

Figure 159: Singapore Human Insulin Market Share, By Type, By Value, 2015-2025F

Figure 160: Singapore Human Insulin Market Share, By Onset Time, By Value, 2015-2025F

Figure 161: Singapore Human Insulin Market Share, By Products, By Value, 2015-2025F

Figure 162: South America Human Insulin Market Size, By Volume (Million Units), By Value (USD Billion), 2015-2025F

Figure 163: South America Human Insulin Market Share, By Indication, By Value, 2015-2025F

Figure 164: South America Human Insulin Market Share, By Brand, By Value, 2015-2025F

Figure 165: South America Human Insulin Market Share, By Route of Administration, By Value, 2015-2025F

Figure 166: South America Human Insulin Market Share, By Type, By Value, 2015-2025F

Figure 167: South America Human Insulin Market Share, By Onset Time, By Value, 2015-2025F

Figure 168: South America Human Insulin Market Share, By Products, By Value, 2015-2025F

Figure 169: South America Human Insulin Market Share, By Country, By Value, 2015-2025F

Figure 170: South America Human Insulin Market Map, By Brand, Market Size (USD Billion) & Growth Rate (%)

Figure 171: Brazil Human Insulin Market Size, By Volume (Million Units), By Value (USD Billion), 2015-2025F

Figure 172: Total Number of Diabetes patients in Brazil, By Value (Millions), 2019, 2030, 2045

Figure 173: Brazil Human Insulin Market Share, By Indication, By Value, 2015-2025F

Figure 174: Brazil Human Insulin Market Share, By Brand, By Value, 2015-2025F

Figure 175: Brazil Human Insulin Market Share, By Route of Administration, By Value, 2015-2025F

Figure 176: Brazil Human Insulin Market Share, By Type, By Value, 2015-2025F

Figure 177: Brazil Human Insulin Market Share, By Onset Time, By Value, 2015-2025F

Figure 178: Brazil Human Insulin Market Share, By Products, By Value, 2015-2025F

Figure 179: Argentina Human Insulin Market Size, By Volume (Million Units), By Value (USD Billion), 2015-2025F

Figure 180: Argentina Health Expenditure (% of GDP), 2015-2019

Figure 181: Argentina Human Insulin Market Share, By Indication, By Value, 2015-2025F

Figure 182: Argentina Human Insulin Market Share, By Brand, By Value, 2015-2025F

Figure 183: Argentina Human Insulin Market Share, By Route of Administration, By Value, 2015-2025F

Figure 184: Argentina Human Insulin Market Share, By Type, By Value, 2015-2025F

Figure 185: Argentina Human Insulin Market Share, By Onset Time, By Value, 2015-2025F

Figure 186: Argentina Human Insulin Market Share, By Products, By Value, 2015-2025F

Figure 187: Colombia Human Insulin Market Size, By Volume (Million Units), By Value (USD Billion), 2015-2025F

Figure 188: Total Number of Diabetes patients in Colombia, By Value (1000’s), 2010, 2019, 2030, 2045

Figure 189: Colombia Human Insulin Market Share, By Indication, By Value, 2015-2025F

Figure 190: Colombia Human Insulin Market Share, By Brand, By Value, 2015-2025F

Figure 191: Colombia Human Insulin Market Share, By Route of Administration, By Value, 2015-2025F

Figure 192: Colombia Human Insulin Market Share, By Type, By Value, 2015-2025F

Figure 193: Colombia Human Insulin Market Share, By Onset Time, By Value, 2015-2025F

Figure 194: Colombia Human Insulin Market Share, By Products, By Value, 2015-2025F

Figure 195: Middle East and Africa Human Insulin Market Size, By Volume (Million Units), By Value (USD Billion), 2015-2025F

Figure 196: Middle East and Africa Human Insulin Market Share, By Indication, By Value, 2015-2025F

Figure 197: Middle East and Africa Human Insulin Market Share, By Brand, By Value, 2015-2025F

Figure 198: Middle East and Africa Human Insulin Market Share, By Route of Administration, By Value, 2015-2025F

Figure 199: Middle East and Africa Human Insulin Market Share, By Type, By Value, 2015-2025F

Figure 200: Middle East and Africa Human Insulin Market Share, By Onset Time, By Value, 2015-2025F

Figure 201: Middle East and Africa Human Insulin Market Share, By Products, By Value, 2015-2025F

Figure 202: Middle East and Africa Human Insulin Market Share, By Country, By Value, 2015-2025F

Figure 203: Middle East & Africa Human Insulin Market Map, By Brand, Market Size (USD Billion) & Growth Rate (%)

Figure 204: Saudi Arabia Human Insulin Market Size, By Volume (Million Units), By Value (USD Billion), 2015-2025F

Figure 205: Total Number of Diabetes patients in Saudi Arabia, By Value (1000’s), 2010, 2019, 2030, 2045

Figure 206: Saudi Arabia Human Insulin Market Share, By Indication, By Value, 2015-2025F

Figure 207: Saudi Arabia Human Insulin Market Share, By Brand, By Value, 2015-2025F

Figure 208: Saudi Arabia Human Insulin Market Share, By Route of Administration, By Value, 2015-2025F

Figure 209: Saudi Arabia Human Insulin Market Share, By Type, By Value, 2015-2025F

Figure 210: Saudi Arabia Human Insulin Market Share, By Onset Time, By Value, 2015-2025F

Figure 211: Saudi Arabia Human Insulin Market Share, By Products, By Value, 2015-2025F

Figure 212: South Africa Human Insulin Market Size, By Volume (Million Units), By Value (USD Billion), 2015-2025F

Figure 213: Total Number of Diabetes patients in South Africa, By Value (1000’s), 2010, 2019, 2030, 2045

Figure 214: South Africa Human Insulin Market Share, By Indication, By Value, 2015-2025F

Figure 215: South Africa Human Insulin Market Share, By Brand, By Value, 2015-2025F

Figure 216: South Africa Human Insulin Market Share, By Route of Administration, By Value, 2015-2025F

Figure 217: South Africa Human Insulin Market Share, By Type, By Value, 2015-2025F

Figure 218: South Africa Human Insulin Market Share, By Onset Time, By Value, 2015-2025F

Figure 219: South Africa Human Insulin Market Share, By Products, By Value, 2015-2025F

Figure 220: UAE Human Insulin Market Size, By Volume (Million Units), By Value (USD Billion), 2015-2025F

Figure 221: UAE Health Expenditure (% of GDP), 2015-2019

Figure 222: UAE Human Insulin Market Share, By Indication, By Value, 2015-2025F

Figure 223: UAE Human Insulin Market Share, By Brand, By Value, 2015-2025F

Figure 224: UAE Human Insulin Market Share, By Route of Administration, By Value, 2015-2025F

Figure 225: UAE Human Insulin Market Share, By Type, By Value, 2015-2025F

Figure 226: UAE Human Insulin Market Share, By Onset Time, By Value, 2015-2025F

Figure 227: UAE Human Insulin Market Share, By Products, By Value, 2015-2025F

Frequently asked questions

Frequently asked questions

The market size of the Global Human Insulin Market was estimated to be USD 24.81 Billion in 2025.

North America is the dominating region in the Global Human Insulin Market.

Biosimilar segment is the fastest growing segment in the Global Human Insulin Market.

The Global Human Insulin Market is expected to grow at 7.51% between 2026 to 2031.

Related Reports

We use cookies to deliver the best possible experience on our website. To learn more, visit our Privacy Policy. By continuing to use this site or by closing this box, you consent to our use of cookies. More info.